Related Experiment Video
Updated: Jun 17, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.6K
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was
Brian E Rittenhouse1, Sultan Alolayan2, Tewodros Eguale1,3
1Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts, USA.
Diabetes, Obesity & Metabolism
|August 14, 2024
Summary
Metformin is not cost-effective for diabetes prevention, contrary to prior analysis. Using standard health economic tools reveals significant monetary and health costs associated with its use.
Area of Science:
- Health economics
- Clinical trial analysis
- Diabetes prevention
Background:
- Oversimplified cost-effectiveness analyses (CEAs) can lead to flawed conclusions.
- The Diabetes Prevention Program (DPP) trial's CEA has been subject to scrutiny regarding its methods.
Purpose of the Study:
- To identify and correct flaws in the original CEA of the DPP trial.
- To re-evaluate the cost-effectiveness of lifestyle interventions versus metformin using standard health economic methods.
Main Methods:
- Revised quality-adjusted life year (QALY) calculations to align with conventional standards.
- Calculated incremental cost-effectiveness ratios (ICERs) using both original and revised QALYs.
- Employed additional health economic tools including net monetary benefits, decision uncertainty assessment, and net losses calculation.
Main Results:
- Both original and revised QALY calculations showed metformin to be technically and economically inefficient.
- Metformin was consistently found to be not cost-effective across all applied methods.
- Decision uncertainty was minimal, with all methods converging on the same conclusion.
Conclusions:
- Lifestyle interventions are cost-effective for diabetes prevention, but metformin is not.
- Misinterpretation of the original DPP CEA resulted in significant monetary and health costs.
- Standard health economic evaluation tools are crucial for accurate interpretation and preventing such misinterpretations.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
01:06Oral Hypoglycemic Agents: Glinides
149
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149
01:15Diabetes: Management and Pharmacotherapy
246
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
246
01:16Insulin: Dosing Regimen and Adverse Effects
161
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
161
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K